Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CRC: early-phase trial registry
10 of 16 indexed CRC trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 10 currently recruiting · #1,060 of 28,707 conditions by registered trial count
CRC: 16 US clinical trials tracked, 10 recruiting.
CRC is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is A2 Biotherapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition crc
OPEN 10 | RECR 63% | LATE 0 | EARLY 14 | RANK #1060 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Gastroesophageal Junction Adenocarcinoma (63% recruiting · 8 trials)
CRC lists 10 open slots (63% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CRC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CRC is recruiting above its size-band peers.
10 of 16 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates CRC research.
A2 Biotherapeutics accounts for 3 of 16 trials (18.8%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical CRC enrolment sits around 200 participants.
Median target enrolment is 200 among the 16 trials that report a genuine target (sentinel values excluded). 6 of those (37.5%) plan for fewer than 100 participants.
-
CRC research is mostly interventional.
15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines
NCT06445062
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06051695
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines
NCT07397338
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis
NCT06657222
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co.
NCT06259552
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Virginia Commonwealth University
NCT06728072
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
NCT07321106
Study to Evaluate D-1553 in Subjects With Solid Tumors
InventisBio Co.
NCT04585035
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
NCT06106308
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
NCT04868773
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Jennerex Biotherapeutics
NCT01394939
Engaging Black Men in Colorectal Cancer Screening
Virginia Commonwealth University
NCT05980182
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co.
NCT05002270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on CRC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CRC trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CRC page
16 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 CRC trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- A2 Biotherapeutics sponsors the most CRC trials on record, review their full trial history before evaluating a specific study. See A2 Biotherapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CRC condition card totals 16 registered trials; most-linked intervention cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.